Shares of Becton Dickinson (NYSE: BDX) plummeted 5.43% in the intraday trading session, after the medical technology company announced plans to separate its Biosciences and Diagnostic Solutions business, while also lowering its fiscal 2025 revenue guidance.
According to the company, the planned separation aims to enhance strategic focus and enable growth-oriented investments and capital allocation for the two businesses. After the separation, the New BD will be a pure-play medical technology company with expected fiscal 2024 revenue of approximately $17.8 billion, while the Biosciences and Diagnostic Solutions business is expected to have around $3.4 billion in revenue.
Meanwhile, Becton Dickinson lowered its fiscal 2025 revenue guidance from the previous range of $21.9 billion to $22.1 billion to a new range of $21.7 billion to $21.9 billion, which fell short of analysts' consensus estimate of $21.93 billion. However, the company raised its adjusted EPS guidance range to $14.30 to $14.60, up from the previous range of $14.25 to $14.60.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。